Published in PLoS One on November 12, 2013
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2014) 1.05
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res (2014) 0.96
The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis (2014) 0.93
New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J Clin Cases (2014) 0.82
RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle (2015) 0.82
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun (2017) 0.78
RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest (2016) 0.78
Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling. Oncotarget (2016) 0.75
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Cancer cell cycles. Science (1996) 21.29
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res (2008) 7.65
Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 6.01
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Deconstructing the molecular portraits of breast cancer. Mol Oncol (2010) 5.37
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer (2008) 5.19
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (1988) 4.15
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80
Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen (2003) 3.15
Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science (1988) 2.83
Molecular stratification of triple-negative breast cancers. Oncologist (2011) 2.81
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat (2009) 2.76
Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat (2008) 2.65
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
Sequence of radiotherapy and chemotherapy in breast cancer after breast-conserving surgery. Int J Radiat Oncol Biol Phys (2012) 1.98
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96
Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst (1996) 1.86
Breast cancer stem cells revealed. Proc Natl Acad Sci U S A (2003) 1.86
Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol (2009) 1.62
RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle (2011) 1.47
Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg (2005) 1.47
High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol (2009) 1.34
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res (2007) 1.23
Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene (1993) 1.15
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem (2010) 1.07
Radiation therapy in the management of primary breast cancer. AJR Am J Roentgenol (1976) 1.06
RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2012) 1.03
Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res (2008) 1.02
Retinoblastoma and p53 gene product expression in breast carcinoma: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol (1992) 0.98
Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med (2010) 0.98
Human retinoblastoma gene: long-range mapping and analysis of its deletion in a breast cancer cell line. Mol Cell Biol (1989) 0.98
Locally recurrent carcinoma of the breast. Results of radiation therapy. Cancer (1976) 0.91
Computational modeling of apoptotic signaling pathways induced by cisplatin. BMC Syst Biol (2012) 0.91
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle (2013) 0.91
Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format. Assay Drug Dev Technol (2011) 0.86
Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother (2009) 0.83
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer. Cancer Chemother Pharmacol (1988) 0.79
Oncogene organisation and expression: prediction in breast cancer. Horm Res (1989) 0.78
The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med (2011) 0.78
Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial. Radiother Oncol (2011) 0.78
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. Int J Hematol (2012) 0.78
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer. Oncology (1990) 0.77
Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients. Cancer Treat Rep (1987) 0.76
HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer. Bone Marrow Transplant (2009) 0.76
Phase II trial with oral idarubicin in advanced breast cancer. Invest New Drugs (1986) 0.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell (2010) 7.51
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther (2006) 3.46
Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer (2007) 3.10
Anoikis resistance and tumor metastasis. Cancer Lett (2008) 2.90
Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res (2007) 2.74
Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell (2011) 2.68
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol (2013) 2.32
Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat Biotechnol (2011) 2.26
Lunatic and manic fringe cooperatively enhance marginal zone B cell precursor competition for delta-like 1 in splenic endothelial niches. Immunity (2009) 2.03
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood (2009) 1.99
High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol (2007) 1.94
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma (2007) 1.70
JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res Treat (2007) 1.69
Activators of cylindrical proteases as antimicrobials: identification and development of small molecule activators of ClpP protease. Chem Biol (2011) 1.68
Global gene deletion analysis exploring yeast filamentous growth. Science (2012) 1.67
Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res (2005) 1.66
Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol (2008) 1.66
Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia (2004) 1.65
Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst (2011) 1.63
Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res (2011) 1.50
RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle (2011) 1.47
Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell (2012) 1.44
Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia. Leuk Lymphoma (2008) 1.42
Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene (2002) 1.41
Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science (2014) 1.39
The Hand1, Stra13 and Gcm1 transcription factors override FGF signaling to promote terminal differentiation of trophoblast stem cells. Dev Biol (2004) 1.38
The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther (2004) 1.37
The retinoblastoma gene pathway regulates the postmitotic state of hair cells of the mouse inner ear. Development (2005) 1.37
Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis. J Cell Biol (2010) 1.36
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Mol Cell (2010) 1.32
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol (2013) 1.30
The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood (2012) 1.27
Stra13 homodimers repress transcription through class B E-box elements. J Biol Chem (2002) 1.25
Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood (2005) 1.24
The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood (2010) 1.24
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol (2009) 1.22
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest (2008) 1.22
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther (2008) 1.21
Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem (2009) 1.20
Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res (2009) 1.18
Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res (2008) 1.17
Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res (2008) 1.16
High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad Sci U S A (2013) 1.16
Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift. J Cell Biol (2010) 1.15
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A (2012) 1.14
Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Res (2011) 1.13
Lunatic Fringe-mediated Notch signaling is required for lung alveogenesis. Am J Physiol Lung Cell Mol Physiol (2009) 1.12
BHLHB2 controls Bdnf promoter 4 activity and neuronal excitability. J Neurosci (2008) 1.12
Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res (2011) 1.10
Effect of noncompetitive proteasome inhibition on bortezomib resistance. J Natl Cancer Inst (2010) 1.09
Coupling of caspase-9 to Apaf1 in response to loss of pRb or cytotoxic drugs is cell-type-specific. EMBO J (2004) 1.09
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood (2010) 1.09
Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood (2008) 1.08
Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther (2007) 1.08
Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme. J Biol Chem (2010) 1.08
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem (2010) 1.07
Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther (2011) 1.04
Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. J Clin Invest (2012) 1.04
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol (2011) 1.04
A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood (2007) 1.03
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. Mol Syst Biol (2013) 1.03
Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther (2010) 1.03
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res (2007) 1.02
Notch signaling in lung development and disease. Adv Exp Med Biol (2012) 1.02
Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J Cell Biol (2002) 1.02
Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One (2012) 1.02
MicroRNA implications across neurodevelopment and neuropathology. J Biomed Biotechnol (2009) 1.01
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat (2008) 1.00
Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett (2011) 1.00
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood (2008) 1.00
Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Sci Transl Med (2011) 1.00